Table 1. Patients' features.

	Absolute number	%
Number of evaluable patients	263	100
Available data about Bevacizumab-chemotherapy	263	100
Gender (male/female)	144/119	54.6/43.4
K-Ras determination (primary vs met)	194/69	73.8/26.2
Second Line	191	72.6
Third Line	122	46.4
Irinotecan based/Oxaliplatin based	201/62	76.4/23.6
Number of involved organs 1 2 3 or more	178 49 36	67.7 18.6 13.7
Cumulative response rate (cPR+cCR)	49%	-
PFS	8.25 months	7.6-8.9
OS	26 months	22-29.9